Stock Movers Sarepta Soars, UPS Falls, Whirlpool Drops on Profit Outlook
Jul 29, 2025
Sarepta's stock skyrockets as the FDA reverses its stance on a gene therapy for patients who can walk. In contrast, UPS faces a downturn after failing to provide full-year revenue guidance amid economic uncertainties. Whirlpool struggles too, slashing its 2025 profit outlook due to disappointing market share and stiff competition from Asian rivals. Join the analysis as they navigate these market highs and lows that reveal broader trends and company challenges.
AI Snips
Chapters
Transcript
Episode notes
FDA Reverses Sarepta Ban
- The FDA allowed ambulatory patients to resume Sarepta's gene therapy Elevidys after a prior pause due to linked deaths.
- Despite the FDA's partial approval, solvency and stock challenges for Sarepta remain substantial.
UPS Faces Uncertain Outlook
- UPS is under performance pressure and declined to give full-year guidance due to macroeconomic uncertainty.
- Efforts to streamline the network and reduced volumes have not yet improved profitability or volume recovery.
Whirlpool's Outlook Slashed
- Whirlpool cut its 2025 profit outlook as U.S. appliance manufacturing benefits haven’t materialized.
- Rival Asian makers escalated promotions causing a slight loss of market share and oversupply pressures.